HK1019560A1 - Formulation for use in the prevention of pathogen induced diseases including hiv and hsv. - Google Patents

Formulation for use in the prevention of pathogen induced diseases including hiv and hsv.

Info

Publication number
HK1019560A1
HK1019560A1 HK99014789A HK99014789A HK1019560A1 HK 1019560 A1 HK1019560 A1 HK 1019560A1 HK 99014789 A HK99014789 A HK 99014789A HK 99014789 A HK99014789 A HK 99014789A HK 1019560 A1 HK1019560 A1 HK 1019560A1
Authority
HK
Hong Kong
Prior art keywords
hsv
formulation
prevention
diseases including
including hiv
Prior art date
Application number
HK99014789A
Other languages
English (en)
Inventor
Michel G Bergeron
Andre Desormeaux
Michel Tremblay
Original Assignee
Infectio Recherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectio Recherche Inc filed Critical Infectio Recherche Inc
Publication of HK1019560A1 publication Critical patent/HK1019560A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK99014789A 1996-05-09 1999-10-27 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv. HK1019560A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1710696P 1996-05-09 1996-05-09
PCT/CA1997/000319 WO1997042962A1 (en) 1996-05-09 1997-05-09 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv

Publications (1)

Publication Number Publication Date
HK1019560A1 true HK1019560A1 (en) 2000-02-18

Family

ID=21780760

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99014789A HK1019560A1 (en) 1996-05-09 1999-10-27 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv.

Country Status (17)

Country Link
US (1) US6068851A (pt)
EP (1) EP0930886B1 (pt)
JP (1) JP2000510836A (pt)
KR (1) KR20000010834A (pt)
CN (1) CN1177594C (pt)
AP (1) AP1406A (pt)
AT (1) ATE269711T1 (pt)
AU (1) AU723081B2 (pt)
BR (1) BR9709228A (pt)
CA (1) CA2258811C (pt)
DE (1) DE69729646T2 (pt)
HK (1) HK1019560A1 (pt)
IL (1) IL126804A0 (pt)
NO (1) NO985148L (pt)
NZ (1) NZ332578A (pt)
OA (1) OA11096A (pt)
WO (1) WO1997042962A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
US6191120B1 (en) 1998-03-25 2001-02-20 Wayne Hughes Institute Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2′,3′-dideoxy-uridines and their pharamaceutical compositions
US6482805B2 (en) * 1998-03-25 2002-11-19 Parker Hughes Institute AZT derivatives exhibiting spermicidal and anti-viral activity
ATE355050T1 (de) * 1998-04-21 2006-03-15 Infectio Recherche Inc Topische formulierung enthaltend poloxamere und weitere mikrobizide
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
CN100488517C (zh) * 2000-03-07 2009-05-20 拉什-长老会-圣路加医学中心 捕获和灭活病原性微生物和精子的组合物及其制药用途
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
EP1335953A4 (en) * 2000-06-23 2005-03-30 Merck & Co Inc POLYNUCLEOTIDE VACCINE ADJUVANTS AND FORMULATIONS CONTAINING CATIONIC SURFACTANTS, METHODS OF USE THEREOF
US7465295B2 (en) 2000-10-20 2008-12-16 Bergeron Michel G Applicator for the delivery of topical formulations into mucosal cavities
WO2003061579A2 (en) * 2002-01-18 2003-07-31 Emory University Phthalocyanine and porphyrazine pharmaceutical compositions
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
WO2004026255A2 (en) * 2002-09-20 2004-04-01 La Jolla Biosciences Compositions and methods for preventing infection
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
US20050014719A1 (en) * 2003-06-24 2005-01-20 Khan Adil A. Method of controlling viral outbreak
US20050095283A1 (en) * 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
WO2005097210A1 (en) * 2004-03-26 2005-10-20 The University Of Utah Research Foundation Bioresponsive polymer system for delivery of microbicides
BRPI0510004A (pt) * 2004-04-20 2007-09-18 Univ Chicago artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
JP2006111585A (ja) * 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
JP5110880B2 (ja) * 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
US20060127459A1 (en) * 2004-12-15 2006-06-15 Lei Huang Urogenital infection inhibition
US20080078408A1 (en) * 2005-04-18 2008-04-03 Park Benjamin W Urethral condoms and liquid female condoms
WO2006112632A1 (en) * 2005-04-18 2006-10-26 Benjamin Won Park Urethral condoms and liquid femidoms
KR100775315B1 (ko) 2005-08-03 2007-11-08 벤자민 원 박 성병과 에이즈예방용 윤활젤 조성물
US20070134747A1 (en) * 2005-12-14 2007-06-14 Kimberly-Clark Worldwide, Inc. Detection of secreted lipase proteins from Candida species
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
CN101662935A (zh) * 2007-05-04 2010-03-03 宝洁公司 抗微生物组合物、产品以及使用方法
US8501230B2 (en) * 2007-12-03 2013-08-06 Trilogic Pharma Llc Self solidifying bioerodible barrier implant
US20110256213A1 (en) * 2008-10-15 2011-10-20 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
DE102009034771B4 (de) * 2009-07-25 2011-09-01 Martin Schmitt Hautschutzmittel
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US20130028959A1 (en) * 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
WO2011153334A2 (en) * 2010-06-04 2011-12-08 Trilogic Pharma Llc Bioadhesive compositions for epithelial drug delivery
EP2849728A1 (en) 2012-05-04 2015-03-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
EP3013368A1 (en) 2013-06-25 2016-05-04 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
WO2016123125A1 (en) 2015-01-27 2016-08-04 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
WO2018011192A1 (en) * 2016-07-12 2018-01-18 Centre National De La Recherche Scientifique Compositions useful for mucosal healing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IT1240354B (it) * 1990-03-30 1993-12-07 Poli Ind Chimica Spa Formulazioni liposomiali di farmaci antimicotici,antibatterici e/o antantiflogistici per applicazione locale e vaginale
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1250748B (it) * 1991-08-02 1995-04-21 Poli Ind Chimica Spa Formulazioni utili per il trattamento della secchezza vaginale
IT1255460B (it) * 1992-07-28 1995-11-02 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
CA2173964A1 (en) * 1993-10-15 1995-04-20 Jess G. Thoene Prevention of hiv infection

Also Published As

Publication number Publication date
CA2258811A1 (en) 1997-11-20
KR20000010834A (ko) 2000-02-25
CN1218403A (zh) 1999-06-02
OA11096A (en) 2003-03-13
BR9709228A (pt) 1999-08-10
CN1177594C (zh) 2004-12-01
ATE269711T1 (de) 2004-07-15
EP0930886A1 (en) 1999-07-28
US6068851A (en) 2000-05-30
JP2000510836A (ja) 2000-08-22
NO985148D0 (no) 1998-11-04
EP0930886B1 (en) 2004-06-23
IL126804A0 (en) 1999-08-17
NZ332578A (en) 2000-06-23
CA2258811C (en) 2003-11-25
DE69729646T2 (de) 2005-07-07
WO1997042962A1 (en) 1997-11-20
AU2629997A (en) 1997-12-05
AP9801382A0 (en) 1998-12-31
AU723081B2 (en) 2000-08-17
DE69729646D1 (de) 2004-07-29
NO985148L (no) 1999-01-08
AP1406A (en) 2005-05-04

Similar Documents

Publication Publication Date Title
HK1019560A1 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv.
ZA989249B (en) Heteroaromatic compounds and their use in medicine.
EP0611168A3 (en) Hop extract and its use.
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
PH31600A (en) Methods of inhibiting atrophy of the skin and vagina.
AU8918998A (en) Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
AU7597898A (en) Use of isoflavonoids in the treatment or prevention of postpartum depression
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
HK1001286A1 (en) Benzopyrans and their use as therapeutic agents.
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
HK1025246A1 (en) The extract of pine needle and the use thereof.
ZA935575B (en) Therapeutic agent and its use.
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
ZA986273B (en) Purine derivatives and the use for medicine thereof.
ZA9711047B (en) Formulation and use.
GB9615435D0 (en) Spray-dried product and its therapeutic use
EP0777523A4 (en) SELF-EMULSIFYING AND EMOLLIENT AGENTS
PH30808A (en) 2-Amino-4-heteroaryl-1,-4-2dihydropyridines and their use in medicaments.
EP1042347A4 (en) PHARMACEUTICAL FORMULATIONS OF DNA COMPRISING CITRATE OR TRIETHANOLAMINE OR COMBINATIONS THEREOF
GB9616504D0 (en) Therapeutic product and its use
ES1027140Y (es) Triturador de pastillas medicinales y similares.
ZA968436B (en) Peptidyl compounds and their therapeutic use.
GB9616508D0 (en) Therapeutic product and its use
GB9616507D0 (en) Therapeutic product and its use
GB9616551D0 (en) Therapeutic product and its use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090509